ArticleFrontiers in pharmacology2025
Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oxaliplatin (OXA) serves as a first-line treatment for digestive system tumors such as colorectal cancer (CRC) and gastric cancer. OXA-induced hypersensitivity reactions (HSRs) may pose life-threatening risks to patients. This study aimed to explore the risk factors and protective factors of OXA-induced HSRs in Chinese CRC patients. Methods: A retrospective analysis was conducted on 233 CRC patients who received OXA treatment between June 2022 and December 2022. Demographic data and medical histories were extracted from the hospital's medical record system. Results: Among the 233 patients, 51 patients (21.9%) developed OXA-induced HSRs, with the median treatment cycle at onset being the 4th cycle. Univariate and multivariate analyses revealed that an OXA treatment interruption lasting ≥30 days (P < 0.05, odds ratio [OR] = 10.76, 95% confidence interval [CI] = 4.57-25.3), a history of platinum-based drug allergy (P < 0.05, OR = 19.03, 95% CI = 1.66-217.99), and abnormal absolute neutrophil count (P < 0.05, OR = 8.96, 95% CI = 3.11-25.86) were independent risk factors. Pretreatment with dual-drug or triple-drug prophylactic regimens before OXA administration was identified as an independent protective factor (P < 0.05, OR = 0.37, 95% CI = 0.17-0.82). The area under the receiver operating characteristic (ROC) curve was 0.82 (P < 0.001, 95% CI = 0.75-0.89). Although previous platinum-based drug dosage and abnormal absolute lymphocyte count showed significant differences in univariate analysis, they did not emerge as independent influencing factors in multivariate logistic regression. Conclusion: Prolonged OXA treatment interruption, a history of platinum-based drug allergy, and abnormal neutrophil count are independent risk factors for OXA-induced HSRs, while dual/triple-drug pretreatment acts as an independent protective factor. Clinicians should evaluate these risks before medication and consider intensified pretreatment regimens to reduce HSR incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.